RGNX REGENXBIO Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RGNX

Price (delayed)

$6.92

Market cap

$357.75M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.6

Enterprise value

$588.88M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 15

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, ...

Highlights
REGENXBIO's debt has surged by 86% YoY but it has decreased by 4.7% QoQ
The quick ratio has declined by 15% year-on-year but it has increased by 3.6% since the previous quarter
The equity has plunged by 92% YoY and by 79% from the previous quarter
The net income has plunged by 84% YoY and by 50% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.regenxbio.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of RGNX

RGNX stock price

How has the REGENXBIO stock price performed over time
Intraday
3.44%
1 week
0.44%
1 month
-26.3%
1 year
-31.35%
YTD
-51.94%
QTD
-17.42%

Financial performance

How have REGENXBIO's revenue and profit performed over time
Revenue
$87.82M
Gross profit
$59.89M
Operating income
-$256.69M
Net income
-$290.01M
Gross margin
68.2%
Net margin
-330.2%
RGNX's operating margin has dropped by 191% year-on-year
REGENXBIO's net margin has shrunk by 190% QoQ
The net income has plunged by 84% YoY and by 50% from the previous quarter
The company's operating income has shrunk by 63% YoY and by 59% QoQ

Price vs fundamentals

How does RGNX's price correlate with its fundamentals

Growth

What is REGENXBIO's growth rate over time

Valuation

What is REGENXBIO stock price valuation
RGNX P/E details
P/E
N/A
P/B
16.94
P/S
4.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.71
RGNX's EPS has dropped by 81% year-on-year and by 49% since the previous quarter
RGNX's P/B is 102% above its last 4 quarters average of 8.1
The equity has plunged by 92% YoY and by 79% from the previous quarter
The company's revenue fell by 48% QoQ and by 44% YoY
The price to sales (P/S) is 38% lower than the 5-year quarterly average of 6.4 but 5% higher than the last 4 quarters average of 3.8

Efficiency

How efficient is REGENXBIO business performance
The ROE has shrunk by 126% QoQ
REGENXBIO's ROA has plunged by 98% YoY and by 61% from the previous quarter
The ROIC has plunged by 56% from the previous quarter and by 45% YoY

Dividends

What is RGNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RGNX.

Financial health

How did REGENXBIO financials performed over time
RGNX's total assets is 7% greater than its total liabilities
RGNX's total liabilities is up by 48% year-on-year but it is down by 8% since the previous quarter
RGNX's total assets is down by 30% year-on-year and by 25% since the previous quarter
The equity has plunged by 92% YoY and by 79% from the previous quarter
REGENXBIO's debt has surged by 86% YoY but it has decreased by 4.7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.